We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Final Six-Month Spending Bill Likely to Neglect Generic, Biosimilar Fees
Final Six-Month Spending Bill Likely to Neglect Generic, Biosimilar Fees
September 14, 2012
The Senate is unlikely to alter a House-approved continuing resolution that will keep the FDA and federal government open through March 27, leaving the agency without permission to collect the newly created generic and biosimilar user fees.